drugset / Trial / NCT02513329

Stellate Ganglion Block (SGB) For Women for Breast Cancer

NCT02513329 ↗

RandomizedParallel-groupSingle-blindSupportive care

Summary

Vasomotor symptoms (VMS) affect up to 65% of breast cancer survivors and negatively impact their quality of life. The investigators aim to evaluate the benefit of SGB in symptomatic women with breast cancer who are on anti-estrogens and are seeking relief from moderate to very severe VMS that are adversely affecting health and wellbeing. Women with breast cancer on Tamoxifen, aromatase inhibitors (AIs) or Selective Estrogen Receptor Modulators (SERMS) with moderate to very severe VMS will be enrolled as participants in this study.

Timeline

Start
2015-07
Primary completion
2020-01
Completion
2020-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bupivicaine Other / unclassified 10 ml Other